Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRRO-110 in Healthy Volunteers and Alpha-1 Antitrypsin Deficiency (REWRITE)
NCT06677307Phase 2Terminated
- Sponsor
- Korro Bio
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
A Phase 2 trial of KRRO-110 in alpha-1 antitrypsin deficiency (AATD), sponsored by Korro Bio. Started Jan 2025; status: terminated.
02
Drugs
KRRO-110
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06677307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677307.